Patent classifications
A61K9/145
EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE
The invention concerns an extruded depot form for sustained active substance release, comprising at least one active substance, at least one first compound from the class of biodegradable organic polymers based on lactic acid and/or glycolic acid and at least one second compound from the class of lipids.
NON-TOBACCO ORAL NICOTINE POUCH COMPOSITION
A non-tobacco oral nicotine pouch composition is provided, including water in an amount of at least 15% by weight of the pouch composition; nicotine; and at least one sugar alcohol, the pouch composition being free of humectants consisting of alginate, propylene glycol, hydroxypropyl cellulose, and glycerol. An oral pouched nicotine product is also provided, including a saliva-permeable pouch and the non-tobacco oral nicotine pouch composition enclosed in the saliva-permeable pouch.
Formulation
A formulation having excellent gastric protection properties comprises an active pharmaceutical ingredient and a waxy compound, dispersed in a pharmaceutically acceptable oily carrier. The formulation presents a palatable and stable oral dosage form which is particularly suitable for acid-sensitive active pharmaceutical ingredients, and which is also suitable for active pharmaceutical ingredients which are liable to cause stomach irritation.
Lipid compound as well as lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing same
The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect. ##STR00001##
LIPID CRYSTALLINE COMPOSITIONS WITH ENHANCED STABILITY FOR TOPICAL DELIVERY OF ACTIVE AGENT COMBINATIONS
Multiple active component therapeutic formulations are described comprising at least two active agents selected from the group consisting of an isovanillin component, a harmine component, and a curcumin component, stabilized in a self-supporting lipid crystalline formulation for topical application. The formulation maintains the active agents in a stable form during storage and will melt at body temperature when applied to the skin, wherein the lipid crystals melt into a liquid crystalline structure thereby releasing the active agents to the applied area of the skin or tissue to render their therapeutic effect.
DEPOSITION OF NANOSUSPENSIONS OF ACTIVE PHARMACEUTICAL INGREDIENTS ON CARRIERS
The present invention provides a method for preparing a pharmaceutical composition of a pharmaceutical ingredient (API) which is loaded on a carrier and stabilized therethrough. In particular, the present invention relates to a composition of a poorly soluble nanoparticulated API on a carrier in the dry state and which is processed as pharmaceutical formulation of said API with improved release profile and bioavailability.
Cannabinoid Products with High Bioavailability
Cannabinoids composition with desirable bioavailability of cannabinoids are provided. In some embodiments, the cannabinoid compositions are modular, and thus, they can be divided into smaller portions so that a user may decide precisely how much they will use. In some embodiments, the cannabinoid compositions can be partially or entirely crushed or chewed by the user as a means of increasing the rate of absorption.
PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF
- Ramasamy VENKATRAGAVAN ,
- Erugu BALAIAH ,
- Paramanandam SENTHILKUMARAN ,
- Guttha JAYAPRASAD ,
- Manniyam Kailasam SELVAM ,
- Noti KRISHNAREDDY ,
- Sorakka Pichandi PARTHIPAN ,
- Murugan ARUNKUMAR ,
- Palaniswamy PREMKUMAR ,
- Salamuthu KALIRAJ ,
- Shanmugam ARUMUGAM ,
- Singavarapu Ajay MADHUKAR ,
- Raman SILAMBARASAN ,
- Saminathan KARTHICK ,
- Kudumudi Jayaraman PARTHIBAN ,
- Ravi SILAMBARASAN
The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.
##STR00001##
Formulations for pharmaceutical agents
A method for forming crystalline solid dispersions (CSDs) of a pharmaceutical agent with low water solubility is described. The properties of the CSDs are described. Also described is the enhancement of bioavailability of the pharmaceutical agent resulting from formation of the CSD.
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof. ##STR00001##